Progressive Multifocal Leukoencephalopathy – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Progressive Multifocal Leukoencephalopathy – Pipeline Review, H2 2017’, provides an overview of the Progressive Multifocal Leukoencephalopathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy

The report reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Progressive Multifocal Leukoencephalopathy therapeutics and enlists all their major and minor projects

The report assesses Progressive Multifocal Leukoencephalopathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Progressive Multifocal Leukoencephalopathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Excision BioTherapeutics Inc

Neurimmune Holding AG

Neuway Pharma GmbH

Pomona Ricerca SRL

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Progressive Multifocal Leukoencephalopathy - Overview 5

Progressive Multifocal Leukoencephalopathy - Therapeutics Development 6

Pipeline Overview 6

Pipeline by Companies 7

Products under Development by Companies 8

Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment 9

Assessment by Target 9

Assessment by Mechanism of Action 11

Assessment by Molecule Type 13

Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development 15

Excision BioTherapeutics Inc 15

Neurimmune Holding AG 15

Neuway Pharma GmbH 15

Pomona Ricerca SRL 16

Progressive Multifocal Leukoencephalopathy - Drug Profiles 17

EBT-103 - Drug Profile 17

Product Description 17

Mechanism Of Action 17

R&D Progress 17

IKT-01427 - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

imatinib mesylate - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

Monoclonal Antibody for JCV and PML Infections - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

NI-307 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

NPW-007 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

PNJC-1 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Progressive Multifocal Leukoencephalopathy - Dormant Projects 25

Progressive Multifocal Leukoencephalopathy - Product Development Milestones 26

Featured News & Press Releases 26

May 21, 2014: Inhibikase Therapeutics Receives Orphan Drug Designation for treatment of Progressive Multifocal Leukoencephalopathy 26

Apr 25, 2013: Inhibikase Therapeutics To Present Data On IkT-001Pro At 5th International Congress On Polyomaviruses And Human Diseases 26

Appendix 28

Methodology 28

Coverage 28

Secondary Research 28

Primary Research 28

Expert Panel Validation 28

Contact Us 28

Disclaimer 29

List of Tables

List of Tables

Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H2 2017 6

Number of Products under Development by Companies, H2 2017 7

Products under Development by Companies, H2 2017 8

Number of Products by Stage and Target, H2 2017 10

Number of Products by Stage and Mechanism of Action, H2 2017 12

Number of Products by Stage and Molecule Type, H2 2017 14

Progressive Multifocal Leukoencephalopathy – Pipeline by Excision BioTherapeutics Inc, H2 2017 15

Progressive Multifocal Leukoencephalopathy – Pipeline by Neurimmune Holding AG, H2 2017 15

Progressive Multifocal Leukoencephalopathy – Pipeline by Neuway Pharma GmbH, H2 2017 16

Progressive Multifocal Leukoencephalopathy – Pipeline by Pomona Ricerca SRL, H2 2017 16

Progressive Multifocal Leukoencephalopathy – Dormant Projects, H2 2017 25

List of Figures

List of Figures

Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H2 2017 6

Number of Products under Development by Companies, H2 2017 7

Number of Products by Targets, H2 2017 9

Number of Products by Stage and Targets, H2 2017 9

Number of Products by Mechanism of Actions, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 11

Number of Products by Molecule Types, H2 2017 13

Number of Products by Stage and Molecule Types, H2 2017 13

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports